Six members of the UH community participated in the inaugural Innov8 Hub's Innovators to Founders Cohort. Photo via UH.edu

A new accelerator at the University of Houston recently wrapped its first program for a cohort of five early-stage startups.

Known as the Innov8 Hub's Innovators to Founders Cohort, the accelerator is a founder-driven program in partnership with the UH Technology Bridge, the Innovation Center, and the Texas Gulf Coast Small Business Development Center (SBDC). Innov8 is designed to aid six to eight aspiring entrepreneurs bring their concepts to market and assist them in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

Founders recently showcased their work before potential partners and investors at the hub's first-ever Startup Pitch Day following the conclusion of the 12-week program.

“The goal of the programs is for the founders to launch new ventures and develop business plans they can use to raise money and attract C-suite level employees to join their team,” Tanu Chatterji, associate director of startup development at Tech Bridge and co-founder of Innov8 Hub, said in a statement. “These programs aren’t classroom-teacher driven so the founders have to commit to engage and spend the time necessary to reap the benefits.”

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program. Photo via UH.edu

The inaugural cohort included:

Shoujun Xu, UForce Biotechnology: Xu is a chemistry professor at UH and has developed a new technique of super-resolution force spectroscopy, or SURFS, and plans to launch his company, UForce Biotechnology, in the future. He aims to use the SURFS technique to advance drug screening. His pitch at the Startup Pitch Day was named the best of the night, and Xu went home with $7,500 in legal services and one year of coworking space free of charge.

Easy Anyama, ODX Health: Anyama is a fourth-year student in the UH College of Optometry. His company, ODX Health, aims to improve "data harmonization, interoperability and integration in eyecare to reduce inefficiencies and enhance health outcomes," according to UH.

Jeremy Tee and Easy Anyama, Ringit: Anyama joined fellow fourth-year student in the UH College of Optometry Jeremy Tee in a second pitch, Ringit. The startup aims to provide a low-cost medication management solution for the visually impaired. It is developing an adaptive labeling system that helps the visually impaired identify their medication and dosages independently via intuitive, "touch-based features," according to UH.

Jan Beetge, AltiSora: Beetge has developed "Botox for wood." The product is made from high- sustainability raw materials that are non-hazardous and non-toxic. Potential applications include waterproofing of electronic equipment or electrical cables or connections in cables, such as cables used in marine applications, according to the company's website.

Jason Shi, Smart Planter Project: Shi is developing a "high-tech planter, a device that autonomously takes care of your plants and keeps them healthy while you’re gone," according to UH. He aims to soon test the product with customers.

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program.

The Innov8 Hub also offers an SBIR/STTR Support Cohort and a WKI Program for Student Entrepreneurial Support Cohort.

Last year, UH also named eight graduate students to its first-ever UH-Chevron Energy Graduate Fellows cohort.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.